Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Medtronic
Boehringer Ingelheim
Mallinckrodt
Colorcon

Last Updated: May 25, 2022

SAVELLA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Savella patents expire, and what generic alternatives are available?

Savella is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in twenty-seven countries.

The generic ingredient in SAVELLA is milnacipran hydrochloride. There are twenty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the milnacipran hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Savella

Savella was eligible for patent challenges on January 14, 2013.

There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for SAVELLA
Drug Prices for SAVELLA

See drug prices for SAVELLA

Drug Sales Revenue Trends for SAVELLA

See drug sales revenues for SAVELLA

Recent Clinical Trials for SAVELLA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of OttawaPhase 4
AllerganPhase 4
New York State Psychiatric InstituteN/A

See all SAVELLA clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for SAVELLA
Paragraph IV (Patent) Challenges for SAVELLA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SAVELLA Tablets milnacipran hydrochloride 12.5 mg, 25 mg, 50 mg, and 100 mg 022256 8 2013-01-14

US Patents and Regulatory Information for SAVELLA

SAVELLA is protected by two US patents.

Patents protecting SAVELLA

Methods of treating fibromyalgia
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF FIBROMYALGIA (FM)

Milnacipran for the long-term treatment of fibromyalgia syndrome
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF FIBROMYALGIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SAVELLA

International Patents for SAVELLA

See the table below for patents covering SAVELLA around the world.

Country Patent Number Title Estimated Expiration
Spain 2395462 See Plans and Pricing
Canada 2493490 See Plans and Pricing
Japan 2012193216 MILNACIPRAN FOR LONG-TERM TREATMENT OF FIBROMYALGIA SYNDROME See Plans and Pricing
Singapore 10201807899P MILNACIPRAN FOR THE LONG-TERM TREATMENT OF FIBROMYALGIA SYNDROME See Plans and Pricing
Costa Rica 9882 MILNACIPRAN PARA EL TRATAMIENTO A LARGO PLAZO DEL SINDROME DE FIBROMIALGIA See Plans and Pricing
Mexico PA05000566 TRATAMIENTO DE DEPRESION SECUNDARIA AL DOLOR (DSP). (TREATMENT OF DEPRESSION SECONDARY TO PAIN (DSP).) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Mallinckrodt
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.